Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Joshua K. Ochieng"'
Autor:
B. Leticia Rodriguez, Limo Chen, Yanli Li, Shucheng Miao, David H. Peng, Jared J. Fradette, Lixia Diao, Jessica M. Konen, Frank R. Rojas Alvarez, Luisa M. Solis, Xiaohui Yi, Aparna Padhye, Laura A. Gibson, Joshua K. Ochieng, Xiaofei Zhou, Jing Wang, Don L. Gibbons
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionDespite significant clinical advancement with the use of immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC) there are still a major subset of patients that develop adaptive/acquired resistance. Understanding resistance
Externí odkaz:
https://doaj.org/article/b7f1eb8f62594da3a8e2703ca0fd91c7
Autor:
David H. Peng, B. Leticia Rodriguez, Lixia Diao, Pierre-Olivier Gaudreau, Aparna Padhye, Jessica M. Konen, Joshua K. Ochieng, Caleb A. Class, Jared J. Fradette, Laura Gibson, Limo Chen, Jing Wang, Lauren A. Byers, Don. L. Gibbons
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
Recent clinical trials combining MEK inhibitors with anti-PD-L1 in solid tumours show moderate responses. Here, the authors demonstrate that the combination of MEK inhibition and PD-L1 blockade in KRAS mutant lung cancer models leads to a transient t
Externí odkaz:
https://doaj.org/article/c550e9da14dd40faac0c52202ab9def2
Autor:
Aparna Padhye, Jessica M. Konen, B. Leticia Rodriguez, Jared J. Fradette, Joshua K. Ochieng, Lixia Diao, Jing Wang, Wei Lu, Luisa S. Solis, Harsh Batra, Maria G. Raso, Michael D. Peoples, Rosalba Minelli, Alessandro Carugo, Christopher A. Bristow, Don L. Gibbons
Publikováno v:
JCI Insight, Vol 6, Iss 17 (2021)
Lack of sustained response to therapeutic agents in patients with KRAS-mutant lung cancer poses a major challenge and arises partly due to intratumor heterogeneity that defines phenotypically distinct tumor subpopulations. To attain better therapeuti
Externí odkaz:
https://doaj.org/article/68b2c3b3409d42f9a4a84381305fc816
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2021)
Checkpoint inhibitors are widely used immunotherapies for advanced cancer. Nonetheless, checkpoint inhibitors have a relatively low response rate, work in a limited range of cancers, and have some unignorable side effects. Checkpoint inhibitors aim t
Externí odkaz:
https://doaj.org/article/8218cd3662084947a22b53587cf69a82
Autor:
Don L. Gibbons, Lauren A. Byers, Jing Wang, Jeffrey J. Kovacs, Robert J. Cardnell, David H. Peng, Jared J. Fradette, Natalie W. Fowlkes, Lixia Diao, Laura Gibson, Joshua K. Ochieng, Aparna Padhye, B. Leticia Rodriguez, Jessica M. Konen
Supplement Figures 1-9 with legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b80fa56b24d34ffc17886269cfe095b
https://doi.org/10.1158/0008-5472.22427014.v1
https://doi.org/10.1158/0008-5472.22427014.v1
Autor:
Don L. Gibbons, Lauren A. Byers, Jing Wang, Jeffrey J. Kovacs, Robert J. Cardnell, David H. Peng, Jared J. Fradette, Natalie W. Fowlkes, Lixia Diao, Laura Gibson, Joshua K. Ochieng, Aparna Padhye, B. Leticia Rodriguez, Jessica M. Konen
Supplementary Tables 1-8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40420440f3fe5ce3d83f8c9e80f2ccf9
https://doi.org/10.1158/0008-5472.22427008
https://doi.org/10.1158/0008-5472.22427008
Autor:
B. Leticia Rodriguez, Limo Chen, Yanil Li, Shucheng Miao, David H. Peng, Jared Fradetta, Lixia Diao, Jessica Marie Konen, Aparna Padhye, Laura Gibson, Joshua K. Ochieng, Xiaofei Zhou, Jing Wang, Don Gibbons
Publikováno v:
Leading Edge of Cancer Research Symposium: Poster Session.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb65586faeb2d93000f22749d7fc7523
https://doi.org/10.52519/00077
https://doi.org/10.52519/00077
Autor:
Joshua K. Ochieng, Luisa S Solis, Harsh Batra, Wei Lu, B. Leticia Rodriguez, Jared J. Fradette, Jessica Konen, Rosalba Minelli, Lixia Diao, Jing Wang, Don L. Gibbons, Christopher A. Bristow, Alessandro Carugo, Aparna Padhye, Michael Peoples, Maria Gabriela Raso
Publikováno v:
JCI Insight
Lack of sustained response to therapeutic agents in patients with KRAS-mutant lung cancer poses a major challenge and arises partly due to intratumor heterogeneity that defines phenotypically distinct tumor subpopulations. To attain better therapeuti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6bfcce065cf6ae3a72658783dd2b5d6
https://pubmed.ncbi.nlm.nih.gov/34309585
https://pubmed.ncbi.nlm.nih.gov/34309585
Autor:
Li Xu, Edwin R. Parra, Alexandre Reuben, Zahraa Rahal, Wei Lu, Carmen Behrens, Kieko Hara, Edwin J. Ostrin, Maria Gabriela Raso, Tina McDowell, Ignacio I. Wistuba, Junya Fukuoka, Luisa M. Solis, Kyle Chang, Florencia McAllister, Jiexin Zhang, Paul Scheet, Warapen Treekitkarnmongkol, Tina Cascone, Humam Kadara, Sayuri Nunomura-Nakamura, Jianling Zhou, Shanshan Deng, Smruthy Sivakumar, Seyed Javad Moghaddam, Joshua K. Ochieng, Junya Fujimoto, Avrum Spira, Maya Hassane, Jacob Kantrowitz, Ansam Sinjab, Wenhua Lang
Publikováno v:
American Journal of Respiratory and Critical Care Medicine
Rationale: Early pathogenesis of lung adenocarcinoma (LUAD) remains largely unknown. We found that, relative to wild-type littermates, the innate immunomodulator Lcn2 (lipocalin-2) was increased in...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c0c399b421590bd726f59608d851f4c
https://pubmed.ncbi.nlm.nih.gov/32846102
https://pubmed.ncbi.nlm.nih.gov/32846102
Autor:
Limo Chen, Joshua K. Ochieng, Jing Wang, Caleb A. Class, Lixia Diao, Jared J. Fradette, Pierre Olivier Gaudreau, B. Leticia Rodriguez, Laura A. Gibson, Lauren Averett Byers, Don L. Gibbons, David H. Peng, Aparna Padhye
Understanding resistance mechanisms to targeted therapies and immune checkpoint blockade in mutant KRAS lung cancers is critical to developing novel combination therapies and improving patient survival. Here, we show that MEK inhibition enhanced PD-L
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f2c4f33ef05d27f31fd8affd22d4671
https://doi.org/10.1101/2020.06.07.136366
https://doi.org/10.1101/2020.06.07.136366